NFKB1 and renal cell carcinoma: First, Sunitinib triggers the activity of pro-tumorigenic NF-kB, through the IRE1α/TRAF2/IKKβ signaling axis, therefore promoting cell survival, as reported in vitro in 786-O RCC cells [47].